Clinical Efficacy of Bevacizumab Combined with Anlotinib in The Treatment of Non-small Cell Lung Cancer and Its Influence on Immune Status
Objective To observe the clinical effect of bevacizumab combined with anlotinib in the treatment of non-small cell lung cancer(NSCLC),and analyze its effect on immune status.Method A prospective randomized controlled study was conducted,selecting non-small cell lung cancer patients as the study subjects.The patients were divided into an observa-tion group and a control group using a random number table method.The control group was treated with anlotinib,and the observation group was treated with anlotinib combined with bevacizumab.The clinical efficacy,T lymphocyte subsets(CD4+,CD3+,CD8+,CD4+/CD8+),vascular endothelial growth factor(VEGF)level,KPS score,tumor marker level[serum carcinoem-bryonic antigen(CEA),carbohydrate antigen 199(CA199),CA125],survival time and adverse drug reactions were compared between the two groups.Results Before treatment,there was no statistical significant difference in various indicators between the two groups of patients(P>0.05).After treatment,the disease control rate(DCR),objective response rate(ORR),CD4+,CD3+,CD4+/CD8+,and KPS scores of the observation group were significantly higher than those of the control group(P<0.05).The levels of CD8+,VEGF,CEA,CA199,and CA125 in the observation group were lower than those in the control group(P<0.05).Following up for 1 year,the median survival time of the observation group patients was 6 months,while the median survival time of the control group patients was 5 months.The total survival time of the observation group patients was significantly longer than that of the control group(lg rank=33.616,P<0.001).There was no statistical significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination of bevacizumab and anlotinib can improve the immune function and functional status of patients with non-small cell lung cancer,prolong the survival period,reduce the expression of tumor markers and VEGF,and has a good clinical effect.
万方数据
维普
